ER+ breast cancer patients tended to have lower levels of sIL-6R when compared to ER- patients, and increased levels of sIL-6R were associated with increased recurrence when compared to patients with lower levels of sIL-6R [80]. Here, IL6R is linked to breast carcinoma.